Public company, workplace, funding, and market signals
Segmed is a Stanford-founded real-world imaging data company that provides a self-serve platform for de-identified medical imaging, reports, and multimodal datasets used by life sciences, medtech, CRO, and academic customers for AI development, clinical research, and real-world evidence.
Primary product
Openda, Segmed's self-serve real-world imaging data platform
Founded
2019
Headquarters
Stanford, California, United States
Team size
11-50
Work style
Remote
Industry
Hospitals and Health Care
Sub-industry
Real-world imaging data platform / healthcare AI data infrastructure
Offices
0 jobs at Segmed
Check back later for new openings
Business model
Stage
Series A
Total raised
$20.4M
Latest round
Series A · Sep 2024
Latest amount
$10.4M
Leadership
CFO
Jie Wu
Co-founder & Chief of Artificial Intelligence Officer
Co-founder & Chief Scientific Officer
Tim Kelly
Chief Data & Operations Officer
CTO & CPO
COO & Head of Data Partnerships
Christian Evans
Vice President of Business Development
Founders
Co-founder & CTO (former)
Co-founder & former CEO
Jie Wu, Ph.D.
Co-founder & Chief of Artificial Intelligence Officer
Investors
Public-facing materials describe a remote, collaborative culture built around transparency, learning mentality, social good, integrity, and personal/professional growth. The company emphasizes mission-driven work in healthcare and data diversity.
Work style
Remote
Compensation
No public compensation bands or salary data were found on the accessible company pages reviewed.
Pricing
No public price sheet found. Public pages indicate subscription access for Openda and validation datasets, plus custom enterprise cohort curation and data licensing / discovery-platform deals.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$1M-$10M
Estimated monthly visits
4.1K
Traffic estimate as of Apr 2026
PRNewswire / Segmed · Jul 2026
Segmed announced a strategic partnership with Nucs AI to combine de-identified imaging and clinical data for oncology biomarker development, real-world evidence, and validation infrastructure; Segmed also said it is making a strategic investment in Nucs AI.
Segmed · Mar 2026
Segmed, with iMerit and Advocate Health, released an annotated breast-tomosynthesis dataset to accelerate breast-cancer AI research and reduce access barriers for researchers.
PRNewswire / Segmed · Feb 2026
Segmed said its curated imaging datasets would become available in Verily's secure AI-native platform to support precision-health research, starting with a breast-cancer cohort.
PRNewswire / Segmed · Jan 2026
Segmed announced independent expert determination confirming de-identification across structured clinical data, imaging pixels, and radiology text, reinforcing its privacy/compliance positioning.
Segmed · May 2025
Segmed appointed David Gascoigne CEO and moved co-founder Martin Willemink to Chief Scientific Officer; Dr. Yin Ho joined the board as an independent director.